ARID1A is a core subunit of SWI/SNF chr1 remodeling complexes that regulates transcription through ATP-dependent alteration of nucleosome structure 1. It serves as a structural scaffold within the BAF complex base module, positioning the ATPase motor to pump DNA along nucleosomes 1. ARID1A functions in both neural development, where it participates in the npBAF-to-nBAF complex transition during neuronal differentiation, and in tissue-specific transcriptional regulation. Disease relevance is substantial: ARID1A is the most commonly mutated SWI/SNF component in human cancers (~6% overall), with particularly high frequencies in ovarian clear cell carcinomas (~45%) and uterine endometrioid cancers (~37%) 2. Loss-of-function ARID1A mutations drive tumorigenesis through multiple mechanisms including dysregulation of PI3K/AKT/mTOR signaling, immune evasion, and altered p53 and KRAS pathway control 2. Notably, ARID1A-deficient tumors exhibit enhanced anti-tumor immunity via R-loop accumulation and STING-dependent type I interferon signaling, conferring improved responsiveness to immune checkpoint blockade 3. Clinically, ARID1A alterations present therapeutic opportunities: immune checkpoint inhibitors, mTOR/EZH2 inhibitors, HDAC inhibitors, and PARP inhibitors show promise 2. Mevalonate pathway inhibition synergizes with immunotherapy in ARID1A-mutant ovarian cancers 4, while estrogen receptor antagonists and bromodomain inhibitors have context-dependent efficacy in ARID1A-altered breast cancers 5.